A Phase 1 interventional study of 11C-ER176 and 11C-PIB in Dementia, sponsored by National Institute of Mental Health (NIMH). Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.
Sponsored by National Institute of Mental Health (NIMH) · Phase 1, Interventional, and Diagnostic
Background:
Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved. Researchers want to see if scans using radioactive drugs can show brain inflammation.
Objective:
To see if the drug [11C]ER176 can show inflammation in the brain in people with certain progressive neurological disorders compared to healthy adults. Also to find genes that might be associated with or cause these disorders.
Eligibility:
People ages 18 and older with an aging-related neurological disorder, and healthy adults
Design:
Participants will be screened with a medical history, physical exam, neurological exam, psychiatric history, and blood tests.
Participants will have 2-5 visits for the first session. They will have 2 PET scans and 1 MRI scan. They may have 3 more sessions: 6 months to about 18 months later, 1 year after that, and about 30 months to 5 years after the first visit. There may be up to 20 total visits.
For the scans, participants will lie on a bed that slides into the scanners. For the PET scans, a strap will fix their head in place. A radioactive drug will be injected through a catheter. A needle will guide a thin plastic tube into an arm vein. Additional catheters may be put in place to draw blood. Each PET will take 2 hours. The MRI will take 30 60 minutes.
At each session, participants will have a brief interview, medical history, physical exam, blood and urine tests, heart tests, and memory and thinking tests. They may donate blood for DNA tests.
Objectives
The primary objective is to explore if human subjects with neurodegenerative diseases exhibit different level of neuroinflammation, as measured by brain uptake of a 3rd generation [11C]ER176 TSPO ligand, compared to control subjects. The secondary objectives are to determine, 1) if [11C]ER176 TSPO brain uptake shows disease-specific patterns across different neurodegenerative diseases and/or genetic mutations, and 2) if longitudinal imaging of individual patients shows a correlation between interval change of tracer uptake and disease progression.
Study population
Adults referred with a clinical diagnosis or with an increased risk of frontotemporal dementia, amyotrophic lateral sclerosis, Alzheimer s disease, other related adult-onset neurodegenerative disorders, or healthy control subjects.
Design
Participants will undergo a general and neurological exam, a standard battery of neuropsychological tests to measure cognitive function, blood tests for analysis of TSPO polymorphisms, MRI of the brain, and PET imaging with the [11C]ER176 TSPO radioligand and [11C]PIB amyloid radioligand. Participants will be invited to return for repeat evaluations approximately 1, 2, and 3-5 years after their initial evaluation.
Outcome measures
Brain PET and MRI scans will be co-registered for anatomic definition of regions of interest, and standard uptake value (SUV) will be calculated in various brain regions. [11C]ER176 PET data will be analyzed with compartmental modeling. [11C]PIB PET and MRI data will be adjunctly used for segregating the collected data by disease subtype. For the primary objective, we will compare TSPO radioligand uptake of healthy controls compared to subjects with neurodegenerative diseases. For secondary objectives, we will determine if neuroanatomical regions of tracer uptake differ across different neurodegenerative disease subtypes, and if interval change of tracer uptake correlates with disease progression in longitudinal imaging of individual subjects.
2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.
This study's enrollment of 13 is below the median of 83 across 1,629 interventional studies indexed under Dementia.
Browse Dementia studies →National Institute of Mental Health (NIMH) is the lead sponsor of 359 studies on the registry; 46 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Are age 18 or older
Have been given a diagnosis by a neurologist of frontotemporal dementia, frontotemporal lobar degeneration, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease, Alzheimer s disease, or other related adult-onset neurodegenerative disease
Have known family history or other risk of an adult-onset genetic neurodegenerative disease, and/or mutation in a gene known to cause an adult-onset neurodegenerative disease
EXCLUSION CRITERIA:
Patients or subjects with an increased risk of neurodegenerative diseases will be excluded if they
Healthy subjects will be excluded if they
Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)
Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan
Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)
Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan
Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PiB followed by brain magnetic resonance imaging (MRI)
Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan
PET biomarker for inflammation
PET biomarker for amyloid
Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB
Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min)
Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and standard uptake value (SUV) was measured over 90 minutes and divided by SUV of the cerebellum to determine difference of \[11C\]ER176 brain uptake
Time frame: Up to 90 minutes during scan
| Milestone | Healthy Volunteers | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | Subjects With Frontotemporal Dementia (FTD) |
|---|---|---|---|
| Started | 6 | 3 | 4 |
| Completed | 6 | 3 | 2 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Withdrawn due to the 2019 pandemic | 0 | 0 | 1 |
Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and standard uptake value (SUV) was measured over 90 minutes and divided by SUV of the cerebellum to determine difference of \[11C\]ER176 brain uptake
| SUV Ratio (SUVR) | Healthy Volunteers | Subjects With Frontotemporal Dementia (FTD) | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) |
|---|---|---|---|
| Dorsolateral Prefrontal Cortex | 1.154816988 ± 0.1068451736460 | 1.243023793 ± 0.20560563 | 0.936561195 ± 0.190544723 |
| Dorsomedial Prefrontal Cortex | 0.996700383 ± 0.071340712 | 0.989731836 ± 0.093928709 | 0.905523672 ± 0.048246962 |
| Orbitofrontal Lobe | 1.217485758 ± 0.088415727 | 1.267286508 ± 0.045403115 | 1.047192088 ± 0.146706043 |
| Perisylvian Cortex, Left | 1.143352336 ± 0.102185733 | 1.132367538 ± 0.049940532 | 1.029305407 ± 0.066022192 |
| Perisylvian Cortex, Right | 1.090685411 ± 0.071228603 | 1.112003017 ± 0.09381086 | 0.941024006 ± 0.055892402 |
| Parietal Lobe, Left | 1.073048863 ± 0.083878696 | 1.034142945 ± 0.01253728 | 0.918176888 ± 0.114668223 |
| Parietal Lobe, Right | 1.020202657 ± 0.069903326 | 1.031347183 ± 0.03211946 | 0.848570905 ± 0.190475917 |
| Medial Temporal Lobe, Left | 1.08451324 ± 0.07643309 | 1.064745227 ± 0.093063402 | 1.032603069 ± 0.036960689 |
| Medial Temporal Lobe, Right | 1.080818839 ± 0.054571041 | 1.126409887 ± 0.037945068 | 1.006852539 ± 0.041618527 |
| Lateral Temporal Lobe, Left | 1.000872064 ± 0.095177072 | 1.009331898 ± 0.006341876 | 0.928285311 ± 0.046290454 |
| Lateral Temporal Lobe, Right | 0.970093545 ± 0.056699904 | 0.953890974 ± 0.022213838 | 0.868920257 ± 0.052268097 |
| Temporal Pole, Left | 1.174033153 ± 0.144718189 | 1.105735482 ± 0.006722645 | 0.951727887 ± 0.184135923 |
| Temporal Pole, Right | 1.083264223 ± 0.089675769 | 1.133115055 ± 0.117352842 | 0.869347972 ± 0.213594461 |
| Occipital Lobe | 1.054680093 ± 0.054134358 | 1.029642393 ± 0.019495596 | 0.971346796 ± 0.048140098 |
| Basal Ganglia + Thalamus | 1.005308052 ± 0.120193318 | 1.000347379 ± 0.046553725 | 0.991325953 ± 0.017050753 |
Collected over Up to 24 hours after each clinic visit for PET scan and MRI. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Volunteers | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Subjects With Frontotemporal Dementia (FTD) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Age, Categorical(Participants) | Healthy Volunteers | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | Subjects With Frontotemporal Dementia (FTD) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 3 | 9 |
| >=65 years | 3 | 0 | 1 | 4 |
| Sex: Female, Male(Participants) | Healthy Volunteers | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | Subjects With Frontotemporal Dementia (FTD) | Total |
|---|---|---|---|---|
| Female | 5 | 2 | 3 | 10 |
| Male | 1 | 1 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Healthy Volunteers | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | Subjects With Frontotemporal Dementia (FTD) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 3 | 4 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Healthy Volunteers | Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72) | Subjects With Frontotemporal Dementia (FTD) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 3 | 4 | 12 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
Documents are hosted by the registry — open the source record to download them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Mental Health (NIMH)